Reforgene Medicine RM001 Pivotal Phase II Beta-Thalassemia Study Achieves Full Transfusion Independence

Reforgene Medicine announced that RM001, its self-developed gene-editing therapy for transfusion-dependent beta-thalassemia, achieved transfusion independence in all enrolled subjects in a pivotal Phase II study, with follow-up exceeding a year. Across all treated subjects to date, hematopoietic reconstitution and freedom from transfusion dependence were achieved, with the longest follow-up reaching five years.